8-K filing — PDS Biotechnology Corp (PDSB)

PDS Biotechnology Announces Publication Of Results From Phase 2 Trial Evaluating PDS0101, HPV16-Targeted Immunotherapy, In Combination With Pembrolizumab In JAMA Oncology, Peer Reviewed Journal Of American Medical Association

39.3 months median overall survival in first-line (1L) R/M immune checkpoint inhibitor naïve patientsCompany continues to prioritize PDS0301 in metastatic colorectal cancer (mCRC) while pursuing partnership strategy for

PDS Biotech Stock Surges Tuesday: What's Driving the Action?

Shares of PDS Biotechnology Corp (NASDAQ: PDSB) are trading sharply higher Tuesday afternoon, extending Monday's gains as investors continue to react to the closing of a multi-tranche financing agreement.

PDS Biotech shares are trading higher. The company announced initial closing of up to $22.3 million PIPE financing.